Gen-Probe Prepares For West Nile Virus Test Commercial Uptake
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe expects an upsurge in revenue from its West Nile Virus blood screening assay shortly after FDA approval, according to CFO and VP-Finance Herm Rosenman
You may also be interested in...
Gen-Probe Aims For Long-Term Growth With Oncological Assays
Gen-Probe will continue to devote a quarter of its revenue to research and development in anticipation of entering the oncology and industrial testing markets
Gen-Probe Aims For Long-Term Growth With Oncological Assays
Gen-Probe will continue to devote a quarter of its revenue to research and development in anticipation of entering the oncology and industrial testing markets
Gen-Probe Cultivates Cancer Segment Through Roche HPV DNA Probe Deal
A supply and purchase agreement with Roche Molecular Systems for human papillomavirus DNA probes could enable Gen-Probe's fledgling oncology segment to introduce an HPV diagnostic in the U.S. by 2009, CEO Henry Nordhoff stated